ALTERITY THERAPEUTICS LIMITED

Contributing Author

Recent Articles by ALTERITY THERAPEUTICS LIMITED

Jun-09	Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy ATHE +9.44% GlobeNewswire
May-19	Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy ATHE GlobeNewswire
May-11	Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy ATHE GlobeNewswire
May-07	Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 ATHE GlobeNewswire
Apr-30	Alterity Therapeutics Releases Appendix 4C - Q3 FY26 Quarterly Cash Flow Report & Corporate Update ATHE GlobeNewswire
Apr-27	Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy ATHE GlobeNewswire
Apr-22	Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology ATHE -6.49% GlobeNewswire
Apr-17	Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors ATHE +12.59% GlobeNewswire
Apr-16	Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting ATHE +6.43% GlobeNewswire
Apr-15	Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy ATHE GlobeNewswire
Mar-30	Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program ATHE +12.97% GlobeNewswire
Mar-09	Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit ATHE GlobeNewswire
Mar-04	Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor ATHE GlobeNewswire
Mar-02	Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments ATHE GlobeNewswire
Jan-30	Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update ATHE GlobeNewswire
Jan-21	Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 ATHE GlobeNewswire
Nov-12	Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference ATHE GlobeNewswire
Nov-10	Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System ATHE +8.27% GlobeNewswire
Oct-31	Alterity Therapeutics: Appendix 4C - Q1 FY26 Quarterly Cash Flow Report ATHE -8.48% GlobeNewswire
Oct-09	Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders ATHE GlobeNewswire
Oct-02	Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders ATHE +6.08% GlobeNewswire
Sep-15	Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting ATHE GlobeNewswire
Sep-08	Alterity Therapeutics Raises A$20.0 million in Strategic Placement ATHE GlobeNewswire
Sep-02	Alterity Therapeutics to Present at the Biotech Showcase ATHE GlobeNewswire
Jul-30	Appendix 4C - Q4 FY25 Quarterly Cash Flow Report ATHE GlobeNewswire
Jul-28	Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy ATHE -14.81% GlobeNewswire
Jul-24	Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study ATHE +13.76% GlobeNewswire
Jun-23	Alterity Therapeutics to Provide Corporate Update in Fireside Chat ATHE GlobeNewswire
May-12	Alterity Therapeutics Prominently Featured at the International MSA Congress ATHE -8.54% GlobeNewswire
May-07	Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress ATHE GlobeNewswire
May-05	Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy ATHE +26.45% GlobeNewswire

ALTERITY THERAPEUTICS LIMITED

Recent Articles by ALTERITY THERAPEUTICS LIMITED

Upgrade your Finviz experience